Non-scale lung cancer immunotherapy! Ono Pharmaceutical Opdivo and Beva monotherapy combination III success: significantly extended progression-free survival.

!--ewebeditor:page title"--August 07, 2020 // -- Ono Pharmaceuticals recently announced anti-PD-1 therapy Opdivo (Odyvo, generic name: ni Positive topline results from phase III clinical study (ONO-4538-52/TASUKI-52) for the treatment of non-squamous non-small cell lung cancer (NSq NSCLC).
results showed that the combination drug combination of Opdivo and Beval monotherapy had significant efficacy, significantly prolonging the life of the disease without progression.
This is a multi-center, randomized, double-blind, placebo-controlled study conducted in patients with advanced (IIIB/IV) or recurrent nonsquamous NSCLC who have not previously received chemotherapy and are not suitable for curative radiotherapy. The efficacy and safety of the Opdivo-Beval monotherapy programme (Opdivo joint group: n-275) and the placebo-beval monotherapy (placebo combination group: n-275) were evaluated.
the study, the Opdivo group received Opdivo (360mg), capa (AUC 6), yew alcohol (200mg/m2), and beva monotherapy (15mg/kg) every 3 weeks (one course).
placebo group received placebo, capil (AUC 6), yew alcohol (200mg/m2), and beva monotherapy (15mg/kg) once every 3 weeks (one course).
2 groups of patients received 4 courses of capa-yew alcohol, if safe, can be treated with up to 6 courses.
, the Opdivo joint group was given Opdivo and beva monothecetic, and the placebo group was given placebo and beva monotoxic until disease progression or unacceptable toxicity was observed.
the main endpoints of the study were progressless survival (PFS) as determined by the Independent Radiology Review Board (IRRC) assessment, with secondary endpoints including total survival (OS), PFS assessed by the study investigators, and objective mitigation rates (ORRs).
results showed that by mid-term analysis, the study had reached a major endpoint: a statistically significant increase in progression-free survival (PFS) in the Opdivo joint group compared to the placebo group.
study, the safety observed by the Opdivo team reflected the known safety of immunospicide inhibitors and NSCLC, a first-line treatment of bevaddin combined chemotherapy.
was first approved in Japan in July 2014 and is the world's first approved PD-1 immunotherapy.
Ono Pharmaceuticals, the original developer of Optivo, in 2011 in a partnership with Permmasch, granted Pershinger's Opdivo development and commercial rights in addition to Japan, South Korea, and Taiwan, China.
July 2014, the two sides further expanded their strategic cooperation to develop and commercialize a variety of immunotherapy (including single-drug and combination therapies) for use in cancer patients in Japan, Korea, and Taiwan, China.
, Opdivo has been listed in more than 60 countries, including Japan, South Korea, China, the United States and the European Union.
Opdivo belongs to PD-(L)1 Oncology Immunotherapy, a procedural death-1 (PD-1) immunos checkpoint inhibitor designed to uniquely use the body's own immune system to help restore anti-tumor immune response by blocking the interaction between PD-1 and its lipens.
by using the body's own immune system to fight cancer, Opdivo has become an important foundational treatment for a wide range of cancers.
bevacizumab is an angiogenestic inhibitor that targets binding vascular endoder growth factors (VEGF).
veGF plays an important role in angiogenesa and maintenance throughout the tumor life cycle.
Avastin infects the tumor's blood supply by binding directly to VEGF, preventing it from interacting with receptors in vascular cells.
blood supply of the tumor is considered to be the key to the tumor's ability to grow and metastase in the body.
has a strong scientific basis for combining Opdivo with beva monoantigen, a combination of Opdivo and bevadding that has the potential to strengthen the immune system against tumors.
in addition to having established anti-angiogenesis effects, bevadding can further enhance the body's ability to restore the body's anti-cancer immunity by inhibiting VEGF-related immunosuppression, promoting T-cell tumor immersion, and initiating T-cell response to tumor antigens.
noteworthy, in December 2018, the FDA approved a new adaptation of Roche's anti-PD-L1 therapy Tecentriq (Tessanchi, generic name: atezolizumab, atelizumab) Symptoms: The Tecentriq-Beva monotherapy (capa-echinacol) programme, first-line treatment of metastatic non-squamous non-small cell lung cancer (NSq NSCLC) without EGFR or ALK genomic tumor distortion.
Data from Group B patients in the IMpower150 study showed that in patients with intentional therapeutic wild type (ITT-WT), Tecentriq and Beva monotherapy significantly extended the total survival of patients compared to Beva monotherapy (median OS: 19.2 months vs 14.7 months, HR?0.78, p.016).
the end of May this year, the FDA approved Tecentriq-Bevamian for the treatment of non-excisible or metastatic hepatocellular carcinoma (HCC) patients who had not previously received systematic treatment.
data from the IMbrave150 clinical trial show that Tecentriq-Avastin combined therapy significantly increased total survival (medium OS:NE vs 13.2 months), reduced risk of death by 42% compared to the standard care drug Sorafenib (HR-0.58, 95%CI:0.42-0.0). 79, p-0.0006), significantly extended disease progression without progression (medium PFS: 6.8 months vs 4.3 months), reduced the risk of disease progression or death by 41% (HR-0.59, 95% CI:0.47-0.76, p.0001).
/!--/ewebeditor:page-!--ewebeditor:page title"--it's worth mentioning that the Tecentriq-Bevad monotherapy combination is the first and only cancer immunotherapy program approved for the treatment of non-excisible or metastatic HCC.
, the program's first-line treatment HCC was accepted by China's National Drug Administration (NMPA) in January and prioritized by the NMPA Drug Review Center (CDE) in February.
source: Opdivo in Commons with Bevacizumab and Changey Shows a Great Progress of Progression-Free Survival in Changey-na?ve Patients with Stage IIIB !--/ewebeditor:page.